Description

VILDADER MET 1000 MG (1X15)

Indications

VILDADER MET 1000 MG is primarily indicated for the management of type 2 diabetes mellitus in adults. It is used as an adjunct to diet and exercise to improve glycemic control in patients whose blood glucose levels are not adequately controlled with lifestyle modifications alone. This medication is particularly beneficial for patients who are overweight or obese and require additional pharmacological intervention to achieve optimal glycemic levels.

Mechanism of Action

VILDADER MET contains two active ingredients: Vildagliptin and Metformin. Vildagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones. These hormones stimulate insulin secretion from the pancreas in response to meals and decrease glucagon secretion, thereby reducing hepatic glucose production. Metformin, on the other hand, primarily works by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The combination of these two mechanisms provides a synergistic effect, leading to better glycemic control.

Pharmacological Properties

VILDADER MET exhibits a unique pharmacological profile due to its dual-action mechanism. Vildagliptin has a rapid onset of action, with peak plasma concentrations typically reached within 1-2 hours after oral administration. It has a half-life of approximately 2 hours, and its effects can last for up to 24 hours, allowing for once-daily dosing. Metformin, on the other hand, has a longer duration of action, with a half-life of about 6 hours. It is primarily excreted unchanged by the kidneys, which necessitates careful monitoring of renal function in patients receiving this medication.

Contraindications

VILDADER MET is contraindicated in patients with a known hypersensitivity to either Vildagliptin or Metformin, as well as those with severe renal impairment (eGFR < 30 mL/min). It should not be used in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, as this may increase the risk of lactic acidosis. Additionally, it is contraindicated in patients with severe hepatic impairment, as the metabolism of Vildagliptin may be affected.

Side Effects

Common side effects associated with VILDADER MET include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. These symptoms are often transient and may improve with continued use. Other potential side effects include hypoglycemia, particularly when used in conjunction with other antidiabetic medications. Rare but serious side effects include lactic acidosis, pancreatitis, and allergic reactions. Patients should be advised to report any unusual symptoms or signs of severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of VILDADER MET is typically 1000 mg once daily, which may be adjusted based on the patient’s glycemic response and tolerance. The maximum recommended dose is 2000 mg per day, divided into two doses. It is essential to take VILDADER MET with food to minimize gastrointestinal side effects and enhance absorption. Regular monitoring of blood glucose levels and renal function is advised to ensure safety and efficacy during treatment.

Interactions

VILDADER MET may interact with other medications, which can either enhance or diminish its effects. Concomitant use of insulin or sulfonylureas may increase the risk of hypoglycemia. Certain medications that affect renal function, such as diuretics or nonsteroidal anti-inflammatory drugs (NSAIDs), may also alter the pharmacokinetics of Metformin, necessitating careful monitoring. Additionally, the use of VILDADER MET with other antidiabetic agents should be approached with caution, and dose adjustments may be required based on individual patient response.

Precautions

Prior to initiating treatment with VILDADER MET, it is crucial to assess the patient’s renal function, as Metformin is contraindicated in patients with significant renal impairment. Patients should be monitored for signs of lactic acidosis, especially in those with conditions that may predispose them to this serious complication, such as severe dehydration, sepsis, or liver disease. Caution should also be exercised in patients with a history of pancreatitis, as there is a potential risk of recurrence. Regular follow-up appointments are essential to evaluate the effectiveness of the treatment and to make any necessary adjustments.

Clinical Studies

Clinical studies have demonstrated the efficacy of VILDADER MET in improving glycemic control in patients with type 2 diabetes. In a randomized, double-blind trial, patients treated with the combination of Vildagliptin and Metformin showed significant reductions in HbA1c levels compared to those receiving Metformin alone. Furthermore, the combination therapy was associated with a lower incidence of hypoglycemia and weight gain compared to other antidiabetic agents. Long-term studies have also indicated that VILDADER MET can help maintain glycemic control over extended periods, making it a valuable option for patients requiring ongoing management of their diabetes.

Conclusion

VILDADER MET 1000 MG is an effective therapeutic option for the management of type 2 diabetes mellitus. Its unique combination of Vildagliptin and Metformin provides a comprehensive approach to glycemic control, addressing multiple aspects of diabetes pathophysiology. While it is generally well-tolerated, healthcare providers must remain vigilant regarding potential side effects and contraindications. Regular monitoring of renal function and blood glucose levels is essential to ensure optimal outcomes for patients using this medication.